Head-To-Head Review: Interpace Biosciences (OTCMKTS:IDXG) versus T2 Biosystems (NASDAQ:TTOO)

Valuation and Earnings

This table compares Interpace Biosciences and T2 Biosystems”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.20	$24.58 million	($0.02)	-89.02
T2 Biosystems	$7.68 million	0.00	-$50.08 million	($3.89)	0.00

Interpace Biosciences has higher revenue and earnings than T2 Biosystems. Interpace Biosciences is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Interpace Biosciences and T2 Biosystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	65.25%	219.07%	105.05%
T2 Biosystems	-563.16%	N/A	-174.06%

Volatility and Risk

Interpace Biosciences has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 8.21, meaning that its share price is 721% more volatile than the S&P 500.

Institutional and Insider Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by insiders. Comparatively, 0.0% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Interpace Biosciences beats T2 Biosystems on 8 of the 11 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.